THE TUMOR ASSOCIATED ANTIGEN-CA15.3 IN PRIMARY BREAST-CANCER - EVALUATION OF 667 CASES

被引:65
作者
GION, M
MIONE, R
NASCIMBEN, O
VALSECCHI, M
GATTI, C
LEON, A
BRUSCAGNIN, G
机构
[1] REG GEN HOSP, DIV RADIOTHERAPY, ULSS 36, MESTRE, ITALY
[2] REG GEN HOSP, DIV RADIOTHERAPY, CTR STUDY BIOL MARKERS MALIGNANCY, ULSS 16, VENICE, ITALY
[3] REG GEN HOSP, SERV PATHOL ANAT, ULSS 36, MESTRE, ITALY
关键词
D O I
10.1038/bjc.1991.179
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes in pT1 tumours. CA15.3 was significantly higher in medullary than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pT1 tumours).
引用
收藏
页码:809 / 813
页数:5
相关论文
共 27 条
[1]   EARLY DETECTION OF BREAST-CANCER RECURRENCES THROUGH PERIODIC FOLLOW-UP - IS IT USELESS [J].
CIATTO, S ;
DELTURCO, MR ;
PACINI, P ;
MUSTACCHI, G ;
SIMONIS, M ;
SISMONDI, P ;
GIARDINA, G ;
BELSANTI, V ;
ARISTEI, C ;
MOLINO, AM ;
CAPELLI, MC ;
AZZINI, V ;
DICOSTANZO, F ;
BUZZI, F ;
MURGO, R ;
PUNZO, C ;
GOSSO, P ;
LOCATELLI, E .
TUMORI, 1985, 71 (04) :325-329
[2]   CIRCULATING CA 15-3 LEVELS IN THE POSTSURGICAL FOLLOW-UP OF BREAST-CANCER PATIENTS AND IN NON-MALIGNANT DISEASES [J].
COLOMER, R ;
RUIBAL, A ;
GENOLLA, J ;
RUBIO, D ;
DELCAMPO, JM ;
BODI, R ;
SALVADOR, L .
BREAST CANCER RESEARCH AND TREATMENT, 1989, 13 (02) :123-133
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   MARKERS IN BREAST-CANCER - DOES CEA ADD TO THE DETECTION BY CA-15.3 [J].
DELARUE, JC ;
MOURIESSE, H ;
DUBOIS, F ;
FRIEDMAN, S ;
MAYLEVIN, F .
BREAST CANCER RESEARCH AND TREATMENT, 1988, 11 (03) :273-276
[5]  
Gion M, 1986, Int J Biol Markers, V1, P33
[6]  
GION M, 1986, J NUCL MED ALLIED S, V30, P29
[7]  
GION M, 1987, NEW TUMOUR MARKERS T, P342
[8]  
HILKENS J, 1984, PROTIDES BIOL FLUIDS, P651
[9]  
HOFFMANN L, 1987, NEW TUMOUR MARKERS T, P74
[10]  
JAGER W, 1986, CLIN RELEVANCE NEW M, P167